Introducing fluorine-18 fluoromisonidazole positron emission tomography for the localisation and quantification of pig liver hypoxia

European Journal of Nuclear Medicine

Volumn 26, Issue 2, 1999, Pages 95-109

  Piert, M ^a   Machulla, H J ^a   Becker, G ^a   Stahlschmidt, A ^a   Patt, M ^a   Aldinger, P ^a   Dissmann P D ^a   Fischer, H ^a   Bares, R ^a   Becker, H D ^a   Lauchart, W ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Fluorine 18 fluoromisonidazole; Liver cell hypoxia; Nitroimidazole imaging; Positron emission tomography

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; FLUORINE 18; MISONIDAZOLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY BLOOD FLOW; ARTERY OCCLUSION; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; FEMALE; HYPOXIA; LIVER; NONHUMAN; OXYGEN CONCENTRATION; OXYGEN TENSION; POSITRON EMISSION TOMOGRAPHY; SWINE;

ANIMALS; CELL HYPOXIA; FEMALE; FLUORINE RADIOISOTOPES; HEMODYNAMIC PROCESSES; HEPATIC ARTERY; LIGATION; LIVER; MISONIDAZOLE; OXYGEN; RADIOPHARMACEUTICALS; SWINE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0006718386     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050365     Document Type: Article

References (51)

1. 2+ and mitochondrial membrane potential preceding cell death in hepatocytes. Nature 1987; 325: 78-81.
2. Luca A, Garcia-Pagan JC, Bosch J, Feu F, Caballeria J, Groszmann RJ, Rodes J. Effects of ethanol consumption on hepatic hemodynamics in patients with alcoholic cirrhosis. Gastroenterology 1997; 112: 1284-1289.
3. Adashi Y, Moore LE, Bradford BU, Gao W, Thurman RG. Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology 1995; 108: 218-224.
4. Arteel GE, Iimuro Y, Yin M, Raleigh JA, Thurman RG. Chronic enteral ethanol treatment causes hypoxia in rat liver tissue in vivo. Hepatology 1997; 25: 920-926.
5. Stubbs M, Rodrigues L, Howe FA, Wang J, Jeong KS, Veech RL, Griffiths JR. Metabolic consequences of a reversed pH gradient in rat tumors. Cancer Res 1994; 54: 4011-4016.
6. Shaw BW, Gordon RD, Iwatsuki S, Starzl TE. Retransplantation of the liver. Semin Liver Dis 1985; 5: 394-401.
7. Forbes RD, Guttman RD, Gomersall M, Hibberd J. A controlled serial ultrastructural tracer study of first-set cardiac allograft rejection in the rat. Am J Pathol 1983; 111: 184-196.
8. Matsumoto Y, McCaughan GW, Painter DM, Bishop GA. Evidence that portal tract microvascular destruction precedes bile duct loss in human liver allograft rejection. Transplantation 1993; 56: 69-75.
9. Gadano A, Durand F, Degott C, Dosguet C, Moreau R, Hadengue A, Widmann JJ, Vachiery F, Elman A, Sogni P, Yang S, Valla D, Bernuau J, Belghiti J, Erlinger S, Lebrec D. Studies of portal hemodynamics and hepatic oxygen consumption during acute liver allograft rejection. Transplantation 1997; 27: 1188-1192.
10. 2 gradients from hemoglobin to cytochrome: new concepts, new complexities. Adv Med Biol 1984; 169: 23-38.
11. 3H]fluoromisonidazole in ischemic myocardium. J Nucl Med 1989; 30: 194-201.
12. Knox RJ, Knight RC, Edwards DI. Studies on the action of nitroimidazole drugs. The products of nitroimidazoles in a radiolytic model system. Int J Radiat Oncol Biol Phys 1983; 10: 1323-1326.
13. Franko AJ. Misonidazole and other hypoxia markers: metabolism and applications. Int J Radiat Oncol Biol Phys 1986; 12: 1195-1202.
14. Whitmore GF, Varghese AJ. The biological properties of reduced nitroheterocyclies and possible underlying biochemical mechanisms. Biochem Pharm 1986; 35: 97-103.
15. Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med 1995; 22: 265-280.
16. Rasey JS, Koh W-J, Grierson JR, Grunbaum Z, Krohn KA. Radiolabeled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys 1989; 17: 985-991.
17. Koh W-J, Bergman KS, Rasey JS, Peterson LM, Evans ML, Graham MM, Grierson JR, Lindsley KL, Lewellen TK, Krohn KA, Griffin TW. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 1995; 33: 391-398.
18. Chapman JD, Baer K, Lee J. Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells. Cancer Res 1983; 43: 1523-1528.
19. 3H]misonidazole in cerebral ischemia. Stroke 1987; 18: 168-176.
20. Liu R-S, Chu L-S, Yen S-H, Chang C-P, Chou K-L, Wu L-C, Chang C-W, Lui M-T, Chen KY, Yeh S-H. Detection of anaerobic odontogenic infections by fluorine-18 fluoromisonidazole. Eur J Nucl Med 1996; 23: 1384-1387.
21. Martin GV, Cerqueira MD, Caldwell JH, Rasey JS, Embree I, Krohn KA. Fluoromisonidazole: a metabolic marker of myocyte hypoxia. Circ Res 1990; 67: 240-244.
22. Shelton ME, Dence CS, Hwang D-R, Welch MJ, Bergmann SR. Myocardial kinetics of fluorine-18 misonidazole: a marker of hypoxic myocardium. J Nucl Med 1989; 30: 351-358.
23. Shelton MC, Dence CS, Hwang D-R, Herrero P, Welch MJ, Bergmann SR. In vivo delineation of myocardial hypoxia during coronary occlusion using fluorine-18 fluoromisonidazole and positron emission tomography: a potential approach for identification of jeopardized myocardium. J Am Coll Cardiol 1990;16: 477-485.
24. Martin GV, Biskupiak JE, Caldwell JH, Rasey JS, Krohn KA. Characterization of iodovinylmisonidazole as a marker for myocardial hypoxia. J Nucl Med 1993; 34: 918-924.
25. Caldwell JH, Revenaugh JR, Martin GV, Johnson PM, Rasey JS, Krohn KA. Comparison of fluorine-18-fluorodeoxyglucose and tritiated fluoromisonidazole uptake during low-flow ischemia. J Nucl Med 1995; 36: 1633-1638.
26. Casciari JJ, Graham MM, Rasey JS. A modeling approach for quantifiying tumor hypoxia with [F-18]fluoromisonidazole PET time-activity data. Med Phys 1995; 22: 1127-1139.
27. Maxwell AP, MacManus MP, Gardiner TA. Misonidazole binding in murine liver tissue: a marker for cellular hypoxia in vivo. Gastroenterology 1989; 97: 1300-1303.
28. McManus ME, Monks A, Collins JM, White R, Strong JM. Nonlinear pharmacokinetics of misonidazole and desmethylmisonidazole in the isolated perfused rat liver. J Pharmacol Exp Ther 1981; 219: 669-674.
29. Smith BR, Born JL, Garcia DJ. Influence of hypoxia on the metabolism and excretion of misonidazole by the isolated perfused rat liver - a model system. Biochem Pharmacol 1983; 32: 1609-1612.
30. 2? Biochem Pharmacol 1987; 36: 3487-3494.
31. Cobb LM, Path FRC, Nolan J. Autoradiographic study of tritium-labeled misonidazole in the mouse. Int J Radiat Oncol Biol Phys 1989; 16: 953-956.
32. 2 tension measurements. Cancer Res 1991; 51: 6098-6102.
33. Terris DJ, Dunphy EP. Oxygen tension measurements of head and neck cancers. Arch Otolaryngol Head Neck Surg 1994; 120: 283-287.
34. Grierson JR, Link JM, Mathis CA, Rasey JS, Krohn KA. A radiosynthesis of fluorine-18 fluoromisonidazole. J Nucl Med 1989; 30: 343-350.
35. 18F]FMISO on different reaction parameters. J Lab Comp Radiopharm 1995; 37: 199-201.
36. DeGrado TR, Turkington TG, Williams JJ, Stearns CW, Hoffman JM, Coleman RE. Performance characteristics of a whole-body PET scanner. J Nucl Med 1994; 35: 1398-1406.
37. Oldhafer KJ. Der Ischämie- und Reperfusionsschaden bei orthotoper Lebertransplantation. Eine tierexperimentelle Studie. In: Beiträge zur Transplantationsmedizin, vol 19. Pabst: Lengerich, 1994.
38. Heymann M, Payne B, Hoffman J, Rudolph A. Blood flow measurements with radionuclide-labeled particles. Prog Cardiovasc Dis 1977; 20: 55-79.
39. Zwissler B, Schlosser R, Weiss C, Iber V, Schwickert C, Spengler P, Messmer K. Methodological error and spatial variability of organ blood flow measurements using radiolabeled microspheres. Res Exp Med Berl 1991; 191: 47-63.
40. Rasey JS, Nelson NJ, Chin L, Evans ML, Grunbaum Z. Characteristics of the binding of labeled fluoromisonidazole in cells in vitro. Radiat Res 1990; 122: 301-308.
41. 3H-labelled misonidazole in the tumor-bearing mouse. Int J Radiat Oncol Bad Phys 1990; 18: 347-351.
42. Parliament MB, Franko AJ, Allalunis-Turner MJ, Mielke BW, Santos CL, Wolokoff BG, Mercer JR. Anomalous patterns of nitroimidazole binding adjacent to necrosis in human glioma xenografts: possible role of decreased oxygen consumption. Br J Cancer 1997; 75: 311-318.
43. Lifson N, Levitt DG, Griffen WO Jr, Ellis CJ. Intrahepatic distribution of hepatic blood flow: double-input studies. Am J Physiol 1970; 218: 1480-1488.
44. Ziegler SI, U Haberkorn, H Byrne, C Tong, R Schosser, H Krieter, S Kaja, Richolt JA, Lammertsma AA, Price P. Measurement of liver blood flow using oxygen-15 labeled water and dynamic positron emission tomography: limitations of model description. Eur J Nucl Med 1996; 23: 169-177.
45. Hales MR, Allan JS, Hall EM. Injection-corrosion studies of normal and cirrhotic livers. Am J Path 1959; 35: 909-941.
46. Mitra SK. The terminal distribution of the hepatic artery with special reference to arterio-portal anastomosis. J Anat 1966; 100: 651-663.
47. Delaney JP. Arteriovenous anastomotic blood flow in the mesenteric organs. Am J Physiol 1969; 216: 1556-1561.
48. Spiegel H-U, Tschuschke C, Holzgreve A, Brown S, Brölsch C, Hauss J. Monitoring of liver oxygenation during neuroleptanalgesia in the dog. J Invest Surg 1992; 5: 315-326.
49. 2-measuring of liver-tissue in warm ischaemia in partial liver resection and ligature of A. hepatica dextra. In: Ehrly AM, Fleckenstein W, Landgraf H, eds. Clinical oxygen pressure measurement. III. Tissue oxygen pressure and transcutaneous oxygen pressure. Berlin: Blackwell, 1992.
50. 3H]nisonidazole binding and paired survival assay. Radiat Res 1996; 145: 491-500.
51. 3H]fluoromisonidazole. Radiat Res 1995; 141: 28-36.